Ax­some's mi­graine drug is­sued CRL a week af­ter the biotech out­lined CMC con­cerns

A week af­ter New York-based Ax­some Ther­a­peu­tics said it ex­pect­ed a CRL for its mi­graine drug, the biotech re­port­ed Mon­day that the FDA has fol­lowed through.

The prin­ci­pal rea­sons giv­en in the CRL are re­lat­ed to chem­istry, man­u­fac­tur­ing and con­trols (CMC) con­sid­er­a­tions, Ax­some re­it­er­at­ed Mon­day. The let­ter iden­ti­fied the need for some ad­di­tion­al CMC da­ta about the drug prod­uct it­self as well as the man­u­fac­tur­ing process, ac­cord­ing to Ax­some. The biotech be­lieves the is­sues raised can be ad­dressed and in­tends to pro­vide po­ten­tial tim­ing for a re­sub­mis­sion fol­low­ing con­sul­ta­tion with the FDA. The let­ter did not raise any ef­fi­ca­cy is­sues, Ax­some said.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER